Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Raymond James from $36.00 to $13.00.
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Participation in Three Upcoming Investor ConferencesGlobeNewswire
- Aaron Rodgers, David Bakhtiari rip Dianne Feinstein over 'unusual' stock trades [FOX News]FOX News
- Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid CongressGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at JMP Securities from $19.00 to $15.00.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Stifel Nicolaus from $8.00 to $7.50.MarketBeat
ALLO
Earnings
- 5/3/23 - Miss
ALLO
Sec Filings
- 5/3/23 - Form 10-Q
- 5/3/23 - Form 8-K
- 4/26/23 - Form 4
- ALLO's page on the SEC website